Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians
- 17 October 2013
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 5 (6), 334-350
- https://doi.org/10.1177/1758834013508197
Abstract
The outcome of patients with metastatic breast cancer (MBC) has clearly improved over the past decades and the proportion of women living with their disease for several years is increasing. However, the usefulness of multiple lines of treatment is still debated and under evaluation. The available data from both randomized trials and large retrospective series are reviewed and discussed in order to analyze management practices, with emphasis on potential prognostic and predictive factors for clinical outcome. At present, evidence-based medicine provides some support for the use of second-line and to a lesser degree and in selected cases, third-line chemotherapy in human epidermal growth factor receptor 2 (HER2) negative MBC. Beyond third-line treatment, messages from recently reported retrospective studies also suggest a clear potential gain for women receiving further therapies after disease progression, since each line can contribute to a longer survival. In HER2-positive disease, the data from observational and retrospective studies support a clinical benefit from the use of trastuzumab beyond disease progression and emerging evidences from randomized controlled trials are leading to the introduction of newer HER2-targeted therapies in multiple lines. The question ‘How many lines of treatment should we give patients?’ clearly needs further research through prospective, high-quality clinical trials, aiming for a better definition of factors with prognostic and predictive role. In the meantime, the ‘optimal’ treatment strategy should probably be to use as many therapeutic options as possible, either in sequence or combination, to keep the best efficacy/toxicity balance, considering MBC as a chronic disease.Keywords
This publication has 82 references indexed in Scilit:
- Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?Anti-Cancer Drugs, 2012
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2011
- Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experienceBritish Journal of Cancer, 2011
- Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective studyBreast Cancer Research and Treatment, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Treatment of metastatic breast cancer: second line and beyondAnnals Of Oncology, 2010
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Research and Treatment, 2010
- International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?JNCI Journal of the National Cancer Institute, 2010
- Is breast cancer survival improving?Cancer, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987